Lumos Pharma is a clinical-stage biopharmaceutical firm committed to developing and selling therapeutics for rare diseases. They are located in Austin, Texas, and have a lead therapeutic candidate known as LUM-201, which is currently being tested in Phase 2 clinical trials to address pediatric growth hormone deficiency and other rare endocrine disorders, and it is an oral growth hormone secretagogue ibutamoren.